![Mark Wiggins](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Wiggins
Director/Board Member at
selectION, Inc.
Profile
Mark C.
Wiggins currently works at selectION, Inc., as Director from 2018.
Mr. Wiggins also formerly worked at Schering Corp., as Marketing Director, Zogenix, Inc., as Independent Director from 2011 to 2022, Schering-Plough Corp., as Head-Business Development from 1986 to 1996, Idera Pharmaceuticals, Inc., as Vice President-Marketing from 1986 to 1998, Biogen, Inc., as Executive VP-Corporate & Business Development from 2003 to 2009, TRACON Pharmaceuticals, Inc., as Chief Business Officer from 2018 to 2022, Elcelyx Therapeutics, Inc., as Senior VP-Corporate & Business Development from 2013 to 2015, Johnson & Johnson Innovation - JJDC, Inc., as Principal, IDEC Pharmaceuticals Corp., as Vice President-Marketing & Business Development from 1998 to 2003, Biogen Idec New Ventures, Inc., as Executive Vice President from 1998 to 2008, MPEX Pharmaceuticals, Inc., as Chief Business Officer from 2009 to 2011, and Vaxcyte, Inc., as Chief Business Officer from 2022 to 2025.
Mr. Wiggins received his undergraduate degree from Syracuse University and Masters Business Admin degree from the University of Arizona.
Mark Wiggins active positions
| Companies | Position | Start |
|---|---|---|
selectION, Inc.
 selectION, Inc. BiotechnologyHealth Technology Provides a technology platform to develop peptide blockers for ion channels | Director/Board Member | 2017-12-31 |
Former positions of Mark Wiggins
| Companies | Position | End |
|---|---|---|
| VAXCYTE, INC. | Corporate Officer/Principal | 2025-04-30 |
| TRACON PHARMACEUTICALS, INC. | Investor Relations Contact | 2022-09-29 |
| ZOGENIX, INC. | Director/Board Member | 2022-03-06 |
Elcelyx Therapeutics, Inc.
 Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics based on gut sensory modulation | Corporate Officer/Principal | 2015-02-28 |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Discovers and develops therapies for antibiotic resistance | Corporate Officer/Principal | 2010-12-31 |
Training of Mark Wiggins
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
82
1st degree connections
15
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 15 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Schering Corp.
 Schering Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets medicines | Health Technology |
TRACON Pharmaceuticals, Inc.
 TRACON Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel targeted therapeutics for cancer treatment | Health Technology |
Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics based on gut sensory modulation | Health Technology |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC invests in private and public companies located across the globe. The firm focuses on innovative medicine, health equity and medtech sectors. It provides financing for seed, early, and later stage capital requirements. | Finance |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes targeted immunotherapies for the treatment of cancer and autoimmune diseases | Health Technology |
Syracuse University
 Syracuse University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Arizona
 University of Arizona Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Discovers and develops therapies for antibiotic resistance | Commercial Services |
selectION, Inc.
selectION, Inc. BiotechnologyHealth Technology Provides a technology platform to develop peptide blockers for ion channels | Health Technology |
Vaxcyte, Inc.
 Vaxcyte, Inc. BiotechnologyHealth Technology Develops vaccines for infectious diseases | Health Technology |
- Stock Market
- Insiders
- Mark Wiggins
